Published on 09 Apr 2013
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.
PDF (538.25 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Our experience with publishing in Perspectives in Medicinal Chemistry has been extraordinary. All of the reviewers provided insightful, fair and constructive comments that helped us to significantly improve our manuscript. The online system constantly informed us about the current stage of manuscript handling. The layout process leading to the final article was done with great care and quality. Thanks for all of this!